Department of Defense Funds ACTION to Advance Duchenne Muscular Dystrophy Cardiac Research
ACTION receives $910,000 Department of Defense award to study the evolving impact of therapies on heart disease in Duchenne muscular dystrophy
Emily Hayes
Use of SGLT2 Inhibitors in Dystrophin Deficient Cardiomyopathy: A Multi-center Study Using the ACTION Registry
A new multicenter study suggests SGLT2 inhibitors — a diabetes drug class — may offer a well-tolerated way to modestly improve heart function in kids with dystrophin-deficient cardiomyopathy.
Dystrophinopathy in ACTION: The first 500 males enrolled in the Advanced Cardiac Therapies Improving Outcomes Network prospective dystrophinopathy registry
Early data from 500 males in the ACTION dystrophinopathy registry show substantial cardiac involvement and broad use of cardioprotective therapies. Ongoing follow-up will define the modern natural history of cardiomyopathy in dystrophinopathy.
Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy
In a prospective study of 265 males with Duchenne Muscular Dystrophy, nearly 30% of those with moderate or severe heart dysfunction were not receiving full consensus-directed cardiac therapy, and most did not reach target medication doses—highlighting the need to optimize treatment strategies as cardiac disease becomes a leading cause of death in DMD.
Cardiac Medication Use in ACTION for Duchenne Muscular Dystrophy Cardiomyopathy Read More »
30th Annual Congress of World Muscle Society – ACTION Oral Presentation
ACTION Oral Presentation Transplant Dystrophinopathy Transplantation in Males with Dystrophinopathy: An Advanced Cardiac Therapies Improving Outcomes Network (ACTION) Dystrophinopathy Registry Analysis Emily Hayes, MD et. al. Download abstract…
30th Annual Congress of World Muscle Society – ACTION Oral Presentation Read More »
Cardiac treatment for Duchenne muscular dystrophy: consensus recommendations from the ACTION muscular dystrophy committee
An expert opinion statement, addressing a critical gap in cardiac care for Duchenne muscular dystrophy – providing thorough recommendations for the initiation and titration of cardiac medications based on disease progression and patient response.
29th Annual Congress of World Muscle Society- ACTION Abstracts Poster Session
What: Poster Session When: Friday, October 11 from 2:15-3:15 pm Dystrophinopathy in ACTION; Analysis of the first 500 males enrolled in the Advanced Cardiac Therapies Improving Outcomes Network prospective
29th Annual Congress of World Muscle Society- ACTION Abstracts Poster Session Read More »
